` 0MH6 (Ipsen SA) vs DAX Index Comparison - Alpha Spread

0MH6
vs
D
DAX Index

Over the past 12 months, 0MH6 has significantly outperformed DAX Index, delivering a return of +73% compared to the DAX Index's +13% growth.

Stocks Performance
0MH6 vs DAX Index

Loading
0MH6
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
0MH6 vs DAX Index

Loading
0MH6
DAX Index
Difference
www.alphaspread.com

Performance By Year
0MH6 vs DAX Index

Loading
0MH6
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Ipsen SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Ipsen SA
Glance View

Market Cap
13.8B EUR
Industry
Pharmaceuticals

Ipsen SA, headquartered in France, is a prominent player in the global biopharmaceutical realm, weaving its story through its commitment to innovation and specialization. Founded in 1929, this family-owned company has evolved significantly, utilizing a diverse mix of scientific research and strategic acquisitions to fuel its growth. Ipsen operates through three principal business segments: Specialty Care, Consumer Healthcare, and Research & Development. Specialty Care, which includes oncology, neuroscience, and rare diseases, is the heart of Ipsen's portfolio, contributing the lion's share of its revenue. The company has honed its focus on developing targeted therapies for complex conditions, leveraging its adeptness in peptide and toxin research. Its success lies in the balance of nurturing homegrown research while acquiring promising biotech firms and novel therapies to expand its offerings and market reach. Beyond its scientific and research prowess, Ipsen's financial robustness stems from a well-orchestrated strategy that intertwines its business operations. The company generates substantial revenue by not only launching innovative products but also through strategic partnerships and licensing agreements that broaden its geographic footprint. Ipsen’s Consumer Healthcare segment complements its operations by delivering over-the-counter products that maintain a steady cash flow, though on a smaller scale compared to Specialty Care. Meanwhile, its Research & Development arm remains the crucible for future growth, as Ipsen invests significantly in pioneering future therapies that align with its core areas of expertise. Through this strategic tapestry, Ipsen has positioned itself as a dynamic entity in the biopharmaceutical industry, consistently striving to deliver value while advancing the frontiers of medicine.

0MH6 Intrinsic Value
150.96 EUR
Overvaluation 10%
Intrinsic Value
Price €167.75
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett